Marksans Pharma Ltd. was started with a vision of reaching the global markets.
To achieve that objective it needs intelligent anticipation of emerging markets which have maximum potential, as well as review of the increasing needs of developing markets.
To envision the Global markets, MPL labs built up a state of the art plant spreading over 18000 sq meters in Goa. The US FDA compliant plant was commissioned in 2001- 02 and received the Australian TGA, UK MHRA and Brazilian ANVISA approval by May 2003.
MPL has achieved remarkable growth during the past two years. Starting with exports to unregulated markets, the company has successively penetrated into the regulated markets.
Main focus markets for MPL is United Kingdom, Australia, New Zealand, Germany and other European markets. MPL is also eying to tab huge Russian and CIS markets and has initiated dossier filling in these countries.
With the approval of UK MHRA, MPL has actively started exporting formulation to UK. MPL has tied up with renowned players in UK markets for the supply of OTC as well as prescription products.
The business model also involves registration of its own dossiers and developing products going off patent 2005 onwards.
About 70 % of export turnover is from United Kingdom. Turnover from Exports from UK is expected to reach USD 10 mn in this financial year.
MPL has already registered 5 products in the Australian markets. MPL also is applying for registration of drugs which are shortly going off patent in Australia. ANZ is the 2nd highest revenue earner for exports after UK.
MPL is also expanding its business in rest of the European markets through Contract manufacturing and active product registrations.
MPL has a strong back up in terms of its formulation development and R & D team aligning itself to aggressive marketing strategies.
MPL has plans to be a very aggressive player in the International field and plans to go in for a US FDA approval by this year. |
